Author:
Bedikian Agop Y.,Wei Caimiao,Detry Michelle,Kim Kevin B.,Papadopoulos Nicholas E.,Hwu Wen-Jen,Homsi Jade,Davies Michael,McIntyre Susan,Hwu Patrick
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference40 articles.
1. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials.;Manola;J Clin Oncol,2000
2. Melanoma Disease Site Group of Cancer Care Ontarios Program in Evidence-based Care. Single-sagent interleukin-2 in the treatment of metastatic melanoma: a systematic review.;Petrella;Cancer Treat Rev,2007
3. Efficacy of interleukin-2 in the treatment of metastatic melanoma: systematic review and meta-analysis.;Allen;Cancer Ther,1998
4. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.;Atkins;J Clin Oncol,1999
5. Phase III trial comparing concurrent biochemotherapy with cisplatin, Vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group.;Atkins;J Clin Oncol,2008
Cited by
58 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献